Cyclo Therapeutics (NASDAQ: CYTH)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-23 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.310 | ||||||
REV | 194.904K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Cyclo Therapeutics (NASDAQ: CYTH) through any online brokerage.
Other companies in Cyclo Therapeutics’s space includes: Immuron (NASDAQ:IMRN), Biocept (NASDAQ:BIOC), T2 Biosystems (NASDAQ:TTOO), Calithera Biosciences (NASDAQ:CALA) and ABVC BioPharma (NASDAQ:ABVC).
The latest price target for Cyclo Therapeutics (NASDAQ: CYTH) was reported by Maxim Group on Thursday, December 17, 2020. The analyst firm set a price target for 12.00 expecting CYTH to rise to within 12 months (a possible 453.00% upside). 0 analyst firms have reported ratings in the last year.
The stock price for Cyclo Therapeutics (NASDAQ: CYTH) is $2.17 last updated Today at August 9, 2022, 8:00 PM UTC.
There are no upcoming dividends for Cyclo Therapeutics.
Cyclo Therapeutics’s Q2 earnings are confirmed for Tuesday, August 23, 2022.
There is no upcoming split for Cyclo Therapeutics.
Cyclo Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.